A Multi-center, Open-label, Four-arm, Randomized Trial Evaluating the Safety and Tolerability of Brivaracetam Intravenous Infusion and Bolus, Administered in BID Regimen as an Adjunctive Antiepileptic Treatment in Subjects From 16 to 70 Years Suffering From Epilepsy.

Trial Profile

A Multi-center, Open-label, Four-arm, Randomized Trial Evaluating the Safety and Tolerability of Brivaracetam Intravenous Infusion and Bolus, Administered in BID Regimen as an Adjunctive Antiepileptic Treatment in Subjects From 16 to 70 Years Suffering From Epilepsy.

Completed
Phase of Trial: Phase III

Latest Information Update: 25 May 2016

At a glance

  • Drugs Brivaracetam (Primary) ; Brivaracetam (Primary)
  • Indications Epilepsy
  • Focus Adverse reactions
  • Sponsors UCB
  • Most Recent Events

    • 25 May 2016 Results published in the Epilepsia
    • 10 Dec 2013 Results presented at the 67th Annual Meeting of the American Epilepsy Society.
    • 28 Jul 2012 Planned number of patients changed from 100 to 125 as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top